19 filings
8-K
MLYS
Mineralys Therapeutics Inc
31 May 24
Financial Statements and Exhibits
4:06pm
8-K
MLYS
Mineralys Therapeutics Inc
22 May 24
Submission of Matters to a Vote of Security Holders
4:38pm
8-K
MLYS
Mineralys Therapeutics Inc
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
8-K
MLYS
Mineralys Therapeutics Inc
4 Apr 24
Departure of Directors or Certain Officers
8:04am
8-K
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
8-K
jmgjn
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
wyl6v
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
8-K
lbhocch 2z2yn5yzdxw
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
c2sy52z q4i
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
m294e
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
r5m25il5bcq2ir
2 Nov 23
Regulation FD Disclosure
10:06am
8-K
q8f10 qtnl5s3
14 Sep 23
Departure of Directors or Certain Officers
4:11pm
8-K
lx4c3xsbi3ie7pmv9
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
j4d43v0op98u8a32vc01
17 Jul 23
Regulation FD Disclosure
4:03pm
8-K
gn4xc p0b508g8ytf
15 May 23
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
qu267ojy50k2 e4r4l
2 May 23
Other Events
8:09am
8-K
9n1orbuyttu trtq3d
21 Mar 23
Departure of Directors or Certain Officers
7:22pm
8-K
39o46aiou13fsv
15 Mar 23
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
npeng kqy3zft
14 Feb 23
Amendments to Articles of Incorporation or Bylaws
4:00pm
- Prev
- 1
- Next